Please login to the form below
GSK loses Viani patent case in Germany
The Federal Patents Court in Germany has ruled against GlaxoSmithKline regarding its patent for Viani, a treatment for asthma and COPD
The Federal Patents Court in Munich, Germany has ruled against GlaxoSmithKline (GSK) regarding its patent for Viani (Seretide), an inhaled respiratory treatment for asthma and chronic obstructive pulmonary disease (COPD).
Mylan, Hexal (part of Novartis' Sandoz), Neolab, and IVAX (owned by Teva) brought the case against GSK to Court.
The Court concluded that under German law GSK's German combination patent for Viani (relating to the combination of the active ingredients salmeterol and fluticasone propionate) was not valid.
GSK is studying the judgment and will be considering an appeal to a higher court.
In a statement, GSK said that "the decision relates solely to the German combination patent for Viani and is not binding in any other jurisdiction".
GSK holds a number of other Viani-related patents in Germany, including patents for the Diskus dry powder inhaler and HFA aerosol formulation, which expire in 2011 and 2012, respectively.
Viani is also known as Advair in other markets. In 2009, the drug accounted for 18 per cent of GSK's revenue and posted sales of $7.8bn.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
-
Senior External Communications Lead
-
£Competitive Salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Account Manager (PR)
-
Great Benefits
-
Account Director
-
£Competitive Salary
-
Account Manager
-
£Competitive Salary
- Sanofi doses first patient in global Kevzara COVID-19 trial
- Moderna chairman says COVID-19 vaccine could begin phase 2 trials in spring
- Germany's coronavirus infections climb but deaths remain low
- Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in UK
- Takeda begins development of COVID-19 plasma therapy
- J&J says COVID-19 vaccine could be ready in early 2021
- We’re Celebrating Ten Magical Years for Ify at Lucid Group
- NICE publishes new COVID-19 management guidelines
- Servier agrees to buy Symphogen to swell its cancer pipeline
- FDA approves expanded use of BMS’ Reblozyl in blood disorders
- Key emerging trends in digital health
- What challenges still face clinical trial recruitment and retention?
PMHub
Bedrock Group
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- What challenges still face clinical trial recruitment and retention?
- Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
- “Fake News” and Credibility in Medical Publishing
- Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
- Delivering true value: what does it mean for KAM in cancer care?
- Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Quick links
Infographics
